By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Combinatorics are presented in a new report. According to news reporting originating in Corvallis, Oregon, by NewsRx journalists, research stated, "A multifunctional tumor-targeting delivery system was developed and evaluated for an efficient treatment of drug-resistant ovarian cancer by combinatorial therapeutic modality based on chemotherapy and mild hyperthermia. The engineered iron oxide nanoparticle (IONPs)-based nanocarrier served as an efficient delivery vehicle for doxorubicin and provided the ability to heat cancer cells remotely upon exposure to an alternating magnetic field (AMP)."
The news reporters obtained a quote from the research from Oregon State University, "The nanocarrier was additionally modified with polyethylene glycol and LHRH peptide to improve its biocompatibility and ability to target tumor cells. The synthesized delivery system has an average size of 97.1 nm and a zeta potential close to zero, both parameters favorable for increased stability in biological media and decreased elimination by the immune system. The nanocarrier demonstrated faster drug release in acidic conditions that mimic the tumor environment. It was also observed that the LHRH targeted delivery system could effectively enter drug resistant ovarian cancer cells, and the fate of doxorubicin was tracked with fluorescence microscope. Mild hyperthermia (40 C) generated by IONPs under exposure to AMF synergistically increased the cytotoxicity of doxorubicin delivered by the developed nanocarrier to cancer cells."
According to the news reporters, the research concluded: "Thus, the developed IONPs-based delivery system has high potential in the effective treatment of ovarian cancer by combinatorial approach."
For more information on this research see: Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells. International Journal of Pharmaceutics, 2013;458(1):169-180. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
Our news correspondents report that additional information may be obtained by contacting O. Taratula, Oregon State University, Sch Elect Engn & Comp Sci, Corvallis, OR 97331, United States. Additional authors for this research include R.K. Dani, C. Schumann, H. Xu, A. Wang, H. Song, P. Dhagat and O. Taratula (see also Combinatorics).
Keywords for this news article include: Drugs, Oregon, Cancer, Oncology, Corvallis, Treatment, Chemotherapy, United States, Combinatorial, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC